Clinical Trial Update: Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib tosylate in patients with recurrent aggressive non-Hodgkin lymphomas has completed, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Cutaneous T-cell Lymphoma
• Diffuse Large B-cell Lymphoma
• Hepatosplenic T-cell Lymphoma
• Immunoblastic Large Cell Lymphoma
• Peripheral T-cell Lymphoma
• T-cell Leukemia Lymphoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2015-09-03